The growth arrest function of the human oncoprotein mouse double minute-2 is disabled by downstream mutation in cancer cells

Cancer Research

Volumn 65, Issue 5, 2005, Pages 1839-1848

  Zhou, Ruizhe ^a   Frum, Rebecca ^a   Deb, Sumitra ^a   Deb, Swati P ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN A; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P16;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN; CELL STRAIN MCF 7; CONTROLLED STUDY; DIPLOIDY; DNA SYNTHESIS; DNA TRANSCRIPTION; GENE DELETION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MUTATION; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN SECRETION;

AMINO ACID SEQUENCE; BASE SEQUENCE; BONE NEOPLASMS; BREAST NEOPLASMS; CYCLIN A; CYCLIN E; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DNA, COMPLEMENTARY; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; OPEN READING FRAMES; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; S PHASE; SEQUENCE DELETION; TUMOR CELLS, CULTURED;

EID: 16444365598     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3755     Document Type: Article

References (58)

1. Meltzer PS. MDM2 and p53: a question of balance. J Natl Cancer Inst 1994;86:1265-6.
2. Juven-Gershon T, Oren M. Mdm2 the ups and downs. Mol Med 1999;5:71-83.
3. Deb SP. Function and dysfunction of the human oncoprotein MDM2. Front Biosci 2002;7:d235-43.
4. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003;1:993-1000.
5. Martin KJ, Graner E, Li Y, et al. High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc Natl Acad Sci U S A 2001;98:2646-51.
6. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
7. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993;13:301-6.
8. Lundgren K, Montes de Oca Luna R, McNeill YB, et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997;11:714-25.
9. Ganguli G, Abecassis J, Wasylyk B. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO J 2000;19:5135-47.
10. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
11. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
12. Brown DR, Deb S, Munoz RM, Subler MA, Deb SP. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein. Mol Cell Biol 1993;13:6849-57.
13. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857-60;
14. Leng P, Brown DR, Shivakumar CV, Deb S, Deb SP. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene 1995;10:1275-82.
15. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
16. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
17. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7.
18. Honda R, Yasuda H. Association of p19 (ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999;18:22-7.
19. Brown DR, Thomas CA, Deb SP. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 1998;17:2513-25.
20. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A 1998;95:15608-12.
21. Steinman HA, Burstein E, Lengner C, et al. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 2004;279:4877-86.
22. Folberg-Blum A, Sapir A, Shilo B, Oren M. Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila. Oncogene 2002;21:2413-7.
23. Dang J, Kuo M, Eischen CM, Stepanova L, Sherr CJ, Roussel MF. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res 2002;62:1222-30.
24. Dellas A, Schultheiss E, Almendral AC, et al. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Int J Cancer 1997;74:421-5.
25. Haidar MA, El-Hajj H, Bueso-Ramos CE, et al. Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance. Am J Hematol 1997;54:189-95.
26. Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 1997;75:1302-8.
27. Tanner B, Hengstler JG, Laubscher S, et al. Mdm2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer 1997;74:438-42.
28. Haines DS, Landers JE, Engle LJ, George DL. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol 1994;14:1171-8.
29. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993;8:2353-60.
30. Gudas J, Nguyen H, Klein R, Katayose D, Seth P, Cowan K. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res 1995;1:71-80.
31. Maxwell SA. Selective compartmentalization of different mdm2 proteins within the nucleus. Anticancer Res 1994;14:2541-7.
32. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996;2:912-7.
33. Lukas J, Gao DQ, Keshmeshian M, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 2001;61:3212-9.
34. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26:3453-9.
35. Deb SP, Deb S, Brown DR. Analysis of the promoter sequences of the UL9 gene of herpes simplex virus type 1. Biochem Biophys Res Commun 1993;193:617-23.
36. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human osteosarcomas. Cancer Res 1993;53:5535-41.
37. Frum RA, Deb SP. Flow cytometric analysis of MDM2-mediated growth arrest In: Deb S, Deb SP, editors. p53 protocols; Methods in Molecular Medicine. USA: Humana Press; 2003. Vol. 234. p. 257-67.
38. Sheikh MS, Shao ZM, Hussain A, Fontana JA The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993;53:3226-8.
39. Marchetti A, Buttitta F, Girlando S, et al. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 1995;175:31-8.
40. McCann AH, Kirley A, Carney DN, et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 1995;71:981-5.
41. Liu XL, Band H, Gao O, Wazer DE, Chu O, Band V. Tumor cell specific loss of p53 protein in a unique in vitro model of human breast tumor progression. Carcinogenesis 1993;15:1969-73.
42. Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and Mdm2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-4.
43. Landers JE, Haines DS, Strauss JF III, George DL. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 1994;9:2745-50.
44. Lander, JE, Cassel SL, George DL. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 1997;57:3562-8.
45. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-9.
46. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994;54:4299-303.
47. Brenner AJ, Stampfer MR, Aidez M. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 1998;17:199-205.
48. Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
49. 1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 2000;101:79-89.
50. Girard F, Strausfeld U, Fernandez A, Lamb NJ. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991;67:1169-79.
51. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992;11:961-71.
52. Mariatos G, Gorgoulis VG, Kotsinas A, et al. Absence of mutations in the functional domains of the human MDM2 oncogene in non-small cell lung carcinomas. Mutation Res 2000;456:59-63.
53. Hori M, Shimazaki J, Inagawa S, Itabashi M, Hori M. Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor α and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat 2002;71:77-83.
54. Silva J, Silva JM, Dominguez G, et al. Absence of point mutation at codon 17 of the Mdm2 gene (serine 17) in human primary tumors. Mutation Res 2000;449:41-5.
55. 1-arrest after DNA damage is associated with constitutive Overexpression of Mdm2, Cdk4, and Irf1 mRNAs in the BALB/c3T3 A31 variant 1-1 clone. Biochem Biophys Res Commun 1997; 233:216-20.
56. Dutta A, Chandra H, Leiter LM, Lester S. Cyclins as markers of tumor proliferation. Proc Natl acad Sci U S A 1995;92:5386-90.
57. Keyomarsi K, Pardee B. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993;90:1112-6.
58. Zhang T, Prives C. Cyclin A-CDK Phosphorylation regulates MDM2 protein interactions. J Biol Chem 2001;276:29702-10.